Summary A recent publication by Crouzier et al. emphasized the utility of zebrafish as a model for investigating rare diseases — enabling better understanding of their underlying mechanisms, and the development of therapeutics to treat these diseases. In this article we will discuss Crouzier et al.’s publication, and InVivo Biosystems’ ongoing work to help identify …
Summary Zebrafish models largely began as a way to research developmental biology, however, their potential to be a preclinical model of human disease quickly became apparent. While the pharmaceutical industry initially invested in zebrafish models, they have yet to widely adopt it – it’s time for that to change. George Stresinger began using zebrafish as …
In this article we discuss Weissbourd’s recent publication as well as GCaMP more broadly, showing how advancing technology has enabled researchers to ask questions that span disciplines and model organism species.
Beyond research into vaccines and traditional therapeutics, the medical community is exploring other ways of helping to prevent, and reduce, symptoms of COVID-19. One promising supplement is a common probiotic. In this article we will discuss the studies that have been conducted, their findings, and answer the question: who could benefit from taking probiotics?
Tauopathies are a type of neurodegenerative disease which get their name from the accumulation of Tau protein that occurs in all of them; these diseases include Alzhiemer’s disease (AD), Pick’s disease, progressive supranuclear palsy, and post-encephalitic parkinsonism, and more. Although there has been a concerted effort to better understand and treat Tau protein aggregation, all tau-targeting therapeutics developed so far have failed. This lack of discovery in the field suggests a better approach is needed to understand Tau protein. In a recent paper, Giong, Subramanian, Yu & Lee (2021) make the case for non-rodent models as a way forwards.
Mutations in the STXBP1 gene are implicated in childhood epilepsies and several neurodevelopmental disorders, however, nearly half of the STXBP1 variants recorded in the ClinVar database are Variants of Unknown Significance (VUS). In a recent publication, members of the InVivo Biosystems team discussed their work creating humanized C. elegans that expressed STXBP1 in order to classify variants as benign or pathogenic.
Rising healthcare costs mean it’s time for pharmaceutical companies to use non-mammalian models in their drug development process — by saving time and money pharmaceutical companies can make a return on their products without sky-high prices for consumers.